$722 Million is the total value of GREAT POINT PARTNERS LLC's 44 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZFGN | New | ZAFGEN INC | $35,805,000 | – | 3,500,000 | +100.0% | 4.96% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $30,540,000 | – | 2,000,000 | +100.0% | 4.23% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INCcall | $27,219,000 | – | 602,200 | +100.0% | 3.77% | – |
| XLRN | New | ACCELERON PHARMA INCput | $26,798,000 | – | 552,300 | +100.0% | 3.71% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $25,617,000 | – | 260,100 | +100.0% | 3.55% | – |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $19,195,000 | – | 169,639 | +100.0% | 2.66% | – |
| VYGR | New | VOYAGER THERAPEUTICS INC | $14,264,000 | – | 730,010 | +100.0% | 1.98% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $13,719,000 | – | 110,506 | +100.0% | 1.90% | – |
| CYTK | New | CYTOKINETICS INC | $11,989,000 | – | 1,444,481 | +100.0% | 1.66% | – |
| EXEL | New | EXELIXIS INCcall | $10,760,000 | – | 500,000 | +100.0% | 1.49% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $9,903,000 | – | 1,473,609 | +100.0% | 1.37% | – |
| XLRN | New | ACCELERON PHARMA INCcall | $5,235,000 | – | 107,900 | +100.0% | 0.73% | – |
| CGEN | New | COMPUGEN LTDord | $2,506,000 | – | 759,494 | +100.0% | 0.35% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $405,000 | – | 804,483 | +100.0% | 0.06% | – |
| NVLNF | New | NOVELION THERAPEUTICS INC | $9,000 | – | 2,500 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| CYTOKINETICS INC | 18 | Q2 2024 | 7.1% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Context Therapeutics Inc. | June 05, 2024 | 7,419,355 | 9.9% |
| Outlook Therapeutics, Inc. | April 08, 2024 | 2,231,324 | 10.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 3,703,433 | 6.4% |
| Avalo Therapeutics, Inc. | February 14, 2024 | 2,085 | 0.3% |
| HERON THERAPEUTICS, INC. /DE/Sold out | February 14, 2024 | 0 | 0.0% |
| Neurogene Inc. | February 14, 2024 | 994,229 | 7.8% |
| OptiNose, Inc. | February 14, 2024 | 11,484,120 | 10.0% |
| PRECISION BIOSCIENCES INCSold out | February 14, 2024 | 0 | 0.0% |
| UroGen Pharma Ltd. | February 14, 2024 | 2,620,545 | 8.5% |
| Vistagen Therapeutics, Inc. | February 14, 2024 | 2,792,927 | 10.0% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| SC 13G | 2024-08-15 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-08-05 |
| SC 13G | 2024-07-18 |
| SC 13G | 2024-06-05 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.